Keith S Kaye1, Tanaya Bhowmick2, Symeon Metallidis3, Susan C Bleasdale4, Olexiy S Sagan5, Viktor Stus6, Jose Vazquez7, Valerii Zaitsev8, Mohamed Bidair9, Erik Chorvat10, Petru Octavian Dragoescu11, Elena Fedosiuk12, Juan P Horcajada13, Claudia Murta14, Yaroslav Sarychev15, Ventsislav Stoev16, Elizabeth Morgan17, Karen Fusaro18, David Griffith17, Olga Lomovskaya17, Elizabeth L Alexander19, Jeffery Loutit17, Michael N Dudley17, Evangelos J Giamarellos-Bourboulis20. 1. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor. 2. Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey. 3. Department of First Internal Medicine, AHEPA Hospital, Medical School, Aristotle University, Thessaloniki, Greece. 4. Department of Medicine, University of Illinois College of Medicine, Chicago. 5. Department of Urology, Regional Clinical Hospital of Zaporizhizhia, Zaporizhizhia, Ukraine. 6. Department of Urology, Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipro. 7. Division of Infectious Diseases, Medical College of Georgia, Augusta University, Augusta. 8. Clinical Studies Department, Bucovinian State Medical University, Chernivtsi, Ukraine. 9. San Diego Clinical Trials, San Diego, California. 10. Department of Urology, Urologicke Oddelenie NSP, Poprad, Slovak Republic. 11. Department of Urology, Craiova Emergency Clinical Hospital, Craiova, Dolj, Romania. 12. Department of Anesthesiology and Intensive Care, Nephrology and Hemocorrection, Brest Regional Hospital, Brest, State Republic of Belarus. 13. Hospital del Mar, Infectious Pathology and Antimicrobials Resaearch Group (IPAR)-Institut Hospital del Mar d'Investigaciones Mèdiques (IMIM), Barcelona, Spain. 14. Department of Infection Control Service, Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil. 15. Department of Urology with Forensic Medicine, Ukrainian Medical Stomatological Academy, Poltava, Ukraine. 16. Department of Urology, Mhat Silistra, Silistra, Bulgaria. 17. The Medicines Company, San Diego, California. 18. Melinta Therapeutics, Parsippany, New Jersey. 19. The Medicines Company, Parsippany, New Jersey. 20. Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece.
Abstract
Importance: Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections. Objective: To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. Design, Setting, and Participants: Phase 3, multicenter, multinational, randomized clinical trial (TANGO I) conducted November 2014 to April 2016 and enrolling patients (≥18 years) with complicated UTI, stratified by infection type and geographic region. Interventions: Eligible patients were randomized 1:1 to receive meropenem-vaborbactam (2g/2g over 3 hours; n = 274) or piperacillin-tazobactam (4g/0.5g over 30 minutes; n = 276) every 8 hours. After 15 or more doses, patients could be switched to oral levofloxacin if they met prespecified criteria for improvement, to complete 10 days of total treatment. Main Outcomes and Measures: Primary end point for FDA criteria was overall success (clinical cure or improvement and microbial eradication composite) at end of intravenous treatment in the microbiologic modified intent-to-treat (ITT) population. Primary end point for European Medicines Agency (EMA) criteria was microbial eradication at test-of-cure visit in the microbiologic modified ITT and microbiologic evaluable populations. Prespecified noninferiority margin was -15%. Because the protocol prespecified superiority testing in the event of noninferiority, 2-sided 95% CIs were calculated. Results: Among 550 patients randomized, 545 received study drug (mean age, 52.8 years; 361 [66.2%] women; 374 [68.6%] in the microbiologic modified ITT population; 347 [63.7%] in the microbiologic evaluable population; 508 [93.2%] completed the trial). For the FDA primary end point, overall success occurred in 189 of 192 (98.4%) with meropenem-vaborbactam vs 171 of 182 (94.0%) with piperacillin-tazobactam (difference, 4.5% [95% CI, 0.7% to 9.1%]; P < .001 for noninferiority). For the EMA primary end point, microbial eradication in the microbiologic modified ITT population occurred in 128 of 192 (66.7%) with meropenem-vaborbactam vs 105 of 182 (57.7%) with piperacillin-tazobactam (difference, 9.0% [95% CI, -0.9% to 18.7%]; P < .001 for noninferiority); microbial eradication in the microbiologic evaluable population occurred in 118 of 178 (66.3%) vs 102 of 169 (60.4%) (difference, 5.9% [95% CI, -4.2% to 16.0%]; P < .001 for noninferiority). Adverse events were reported in 106 of 272 (39.0%) with meropenem-vaborbactam vs 97 of 273 (35.5%) with piperacillin-tazobactam. Conclusions and Relevance: Among patients with complicated UTI, including acute pyelonephritis and growth of a baseline pathogen, meropenem-vaborbactam vs piperacillin-tazobactam resulted in a composite outcome of complete resolution or improvement of symptoms along with microbial eradication that met the noninferiority criterion. Further research is needed to understand the spectrum of patients in whom meropenem-vaborbactam offers a clinical advantage. Trial Registration: clinicaltrials.gov Identifier: NCT02166476.
RCT Entities:
Importance: Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections. Objective: To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. Design, Setting, and Participants: Phase 3, multicenter, multinational, randomized clinical trial (TANGO I) conducted November 2014 to April 2016 and enrolling patients (≥18 years) with complicated UTI, stratified by infection type and geographic region. Interventions: Eligible patients were randomized 1:1 to receive meropenem-vaborbactam (2g/2g over 3 hours; n = 274) or piperacillin-tazobactam (4g/0.5g over 30 minutes; n = 276) every 8 hours. After 15 or more doses, patients could be switched to oral levofloxacin if they met prespecified criteria for improvement, to complete 10 days of total treatment. Main Outcomes and Measures: Primary end point for FDA criteria was overall success (clinical cure or improvement and microbial eradication composite) at end of intravenous treatment in the microbiologic modified intent-to-treat (ITT) population. Primary end point for European Medicines Agency (EMA) criteria was microbial eradication at test-of-cure visit in the microbiologic modified ITT and microbiologic evaluable populations. Prespecified noninferiority margin was -15%. Because the protocol prespecified superiority testing in the event of noninferiority, 2-sided 95% CIs were calculated. Results: Among 550 patients randomized, 545 received study drug (mean age, 52.8 years; 361 [66.2%] women; 374 [68.6%] in the microbiologic modified ITT population; 347 [63.7%] in the microbiologic evaluable population; 508 [93.2%] completed the trial). For the FDA primary end point, overall success occurred in 189 of 192 (98.4%) with meropenem-vaborbactam vs 171 of 182 (94.0%) with piperacillin-tazobactam (difference, 4.5% [95% CI, 0.7% to 9.1%]; P < .001 for noninferiority). For the EMA primary end point, microbial eradication in the microbiologic modified ITT population occurred in 128 of 192 (66.7%) with meropenem-vaborbactam vs 105 of 182 (57.7%) with piperacillin-tazobactam (difference, 9.0% [95% CI, -0.9% to 18.7%]; P < .001 for noninferiority); microbial eradication in the microbiologic evaluable population occurred in 118 of 178 (66.3%) vs 102 of 169 (60.4%) (difference, 5.9% [95% CI, -4.2% to 16.0%]; P < .001 for noninferiority). Adverse events were reported in 106 of 272 (39.0%) with meropenem-vaborbactam vs 97 of 273 (35.5%) with piperacillin-tazobactam. Conclusions and Relevance: Among patients with complicated UTI, including acute pyelonephritis and growth of a baseline pathogen, meropenem-vaborbactam vs piperacillin-tazobactam resulted in a composite outcome of complete resolution or improvement of symptoms along with microbial eradication that met the noninferiority criterion. Further research is needed to understand the spectrum of patients in whom meropenem-vaborbactam offers a clinical advantage. Trial Registration: clinicaltrials.gov Identifier: NCT02166476.
Authors: Pranita D Tamma; Edina Avdic; John F Keenan; Yuan Zhao; Gobind Anand; James Cooper; Rebecca Dezube; Steven Hsu; Sara E Cosgrove Journal: Clin Infect Dis Date: 2017-03-01 Impact factor: 9.079
Authors: Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas Journal: Emerg Infect Dis Date: 2014-07 Impact factor: 6.883
Authors: Elizabeth L Alexander; Jeffery Loutit; Mario Tumbarello; Richard Wunderink; Tim Felton; George Daikos; Karen Fusaro; Dan White; Shu Zhang; Michael N Dudley Journal: Open Forum Infect Dis Date: 2017-06-01 Impact factor: 3.835
Authors: Florian M Wagenlehner; Jack D Sobel; Paul Newell; Jon Armstrong; Xiangning Huang; Gregory G Stone; Katrina Yates; Leanne B Gasink Journal: Clin Infect Dis Date: 2016-06-16 Impact factor: 9.079
Authors: Joseph D Lutgring; Anny Kim; Davina Campbell; Maria Karlsson; Allison C Brown; Eileen M Burd Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo Journal: Infect Dis Clin North Am Date: 2020-09-30 Impact factor: 5.982
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-11 Impact factor: 1.041